Adegun Patrick Temi, Adebayo Philip Babatunde, Atiba Samuel Adeniran
Department of Surgery, College of Medicine, Ekiti State University, Ado-Ekiti, Ekiti State, Nigeria.
Department of Medicine, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Asian J Urol. 2015 Jul;2(3):158-162. doi: 10.1016/j.ajur.2015.06.004. Epub 2015 Jun 24.
This study was undertaken to determine the likelihood of having serum total prostate specific antigen (PSA) levels ≥4.0 ng/mL and ≥10.0 ng/mL among a cohort of non-obese and obese Nigerian men with lower urinary tract symptoms (LUTS).
This was a prospective cross-sectional survey among men who presented with benign prostatic hypertrophy to the urology clinic of the Ekiti State University Teaching Hospital, Ado -Ekiti with LUTS between January 1 and December 31, 2014. One hundred and forty men who presented in the urologic clinic with LUTS were recruited. PSA was analyzed using standard method while other clinical variables were collected using a clinical case form. Multivariate logistic regression was used to estimate the odds of an abnormal PSA of ≥4.0 ng/mL or ≥10.0 ng/mL in these men.
The mean ages of obese and non-obese men were 64.8 and 64.0 years respectively. The mean total serum PSA were 14.8 and 13.2 ng/mL for obese and non-obese men respectively. Univariate analysis showed no difference ( > 0.05) in the proportion of obese and non-obese men with LUTS who had a PSA threshold of at least 4.0 ng/mL. Multivariate logistic regression showed that, at a PSA threshold of 10.0 ng/mL, obese men had a statistically significant proportion ( < 0.05). Although not significant, non-obese patients were less likely to have PSA level of ≥4.0 ng/mL (OR 0.701; 95% CI 0.301-1.630) compared to obese men. In the same vein, non-obese men were less likely to have a PSA level of 10.0 ng/mL (OR, 0.686; 95% CI, 0.318-1.478) in a simultaneous context of age.
Our study demonstrated that, in a sample population of predominantly native African men, there was a non-significantly higher likelihood of overweight/obese patients having a higher serum PSA level than the non-obese. A community based study is needed to further confirm this finding.
本研究旨在确定一组有下尿路症状（LUTS）的非肥胖和肥胖尼日利亚男性中血清总前列腺特异性抗原（PSA）水平≥4.0 ng/mL和≥10.0 ng/mL的可能性。
这是一项对2014年1月1日至12月31日期间因良性前列腺增生到埃基蒂州立大学教学医院阿多 - 埃基蒂泌尿外科门诊就诊且有LUTS的男性进行的前瞻性横断面调查。招募了140名到泌尿外科门诊就诊且有LUTS的男性。采用标准方法分析PSA，同时使用临床病例表收集其他临床变量。使用多因素逻辑回归来估计这些男性中PSA异常（≥4.0 ng/mL或≥10.0 ng/mL）的几率。
肥胖男性和非肥胖男性的平均年龄分别为64.8岁和64.0岁。肥胖男性和非肥胖男性的血清总PSA平均水平分别为14.8 ng/mL和13.2 ng/mL。单因素分析显示，有LUTS且PSA阈值至少为4.0 ng/mL的肥胖男性和非肥胖男性比例无差异（P>0.05）。多因素逻辑回归显示，在PSA阈值为10.0 ng/mL时，肥胖男性的比例具有统计学意义（P<0.05）。与肥胖男性相比，非肥胖患者PSA水平≥4.0 ng/mL的可能性虽不显著，但较低（比值比0.701；95%置信区间0.301 - 1.630）。同样，在年龄相同的情况下，非肥胖男性PSA水平为10.0 ng/mL的可能性也较低（比值比，0.686；95%置信区间，0.318 - 1.478）。
我们的研究表明，在以非洲本土男性为主的样本人群中，超重/肥胖患者血清PSA水平高于非肥胖患者的可能性虽无显著差异，但略高。需要开展基于社区的研究来进一步证实这一发现。
